{"id":"W2939153131","doi":"10.2340/00015555-3195","title":"Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials","year":2019,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Allergan; LEO Pharma; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; National Psoriasis Foundation; Valeant Pharmaceuticals International; Endo International; Sanofi; Galderma; Ortho Dermatologics; Eli Lilly and Company; Amgen","keywords":"Secukinumab; Itching; Medicine; Placebo; Psoriasis; Randomized controlled trial; Clinical trial; Pain relief; Dermatology; Physical therapy; Alternative medicine; Surgery; Internal medicine; Psoriatic arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00579599,0.0006599248,0.003424089,0.0001959524,0.0001984706,0.00009362102,0.0006702859,0.0005711255,0.0006431085],"category_scores_gemma":[0.004016957,0.0004182093,0.0003025011,0.0001564213,0.0001662937,0.0003915366,0.0005020829,0.0004671379,0.0002055589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005843601,"about_ca_system_score_gemma":0.0001383863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004566993,"about_ca_topic_score_gemma":0.00009003206,"domain_scores_codex":[0.9827384,0.01313845,0.001954978,0.001384824,0.0001532698,0.0006300853],"domain_scores_gemma":[0.9825167,0.0150757,0.0009126341,0.0012855,0.00008107795,0.000128359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7651861,0.001783377,0.08993918,0.00001618724,0.003509833,0.00004959033,0.0009561229,0.00005533261,0.0009238846,0.00002116687,0.002090944,0.1354683],"study_design_scores_gemma":[0.9830985,0.001247705,0.007808818,0.0002907455,0.001327477,0.00000821966,0.0003285091,0.00132771,0.0008053783,0.0005188456,0.002341774,0.0008962866],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885943,0.003689524,0.0001447192,0.0003394368,0.000909259,0.004850923,0.001215275,0.0001172305,0.0001393506],"genre_scores_gemma":[0.9924191,0.0004467616,0.0007062512,0.0008811809,0.0001116266,0.0004273525,0.004913887,0.00004710896,0.00004678968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2179125,"threshold_uncertainty_score":0.999827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03243579517012712,"score_gpt":0.2977604257043597,"score_spread":0.2653246305342326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}